0001104659-26-042666
SEC filingSolana Company announced the mutual separation of Chief Medical Officer Antonella Favit-Van Pelt, MD, PhD, effective April 8, 2026, with a $875,000 lump sum separation payment.
The departure of Solana Company's Chief Medical Officer, a key leadership role likely central to clinical and medical strategy, occurred via mutual agreement without disclosed discord. The $875,000 separation payment, provided in exchange for a comprehensive release of claims, full satisfaction of prior obligations, and ongoing confidentiality commitments, underscores a clean exit. Vesting of only 18,037 stock options as of the separation date limits equity exposure, while cessation of benefits on April 30, 2026, aligns with standard practices. Investors should note the absence of a named successor, potentially signaling interim leadership needs in medical affairs.